After years of success with their diagnostic platform for COVID-19, tuberculosis and the flu, the family funded company is shifting priorities back to the vaccine market.
After years of success with their diagnostic platform for COVID-19, tuberculosis and the flu, the family funded company is shifting priorities back to the vaccine market.
Copyright © 2024 | WordPress Theme by MH Themes